ECSP088467A - Formulaciones de quinolinonas - Google Patents

Formulaciones de quinolinonas

Info

Publication number
ECSP088467A
ECSP088467A EC2008008467A ECSP088467A ECSP088467A EC SP088467 A ECSP088467 A EC SP088467A EC 2008008467 A EC2008008467 A EC 2008008467A EC SP088467 A ECSP088467 A EC SP088467A EC SP088467 A ECSP088467 A EC SP088467A
Authority
EC
Ecuador
Prior art keywords
quinolinone
formulations
compound
tautomer
salt
Prior art date
Application number
EC2008008467A
Other languages
English (en)
Inventor
Augustus Okhamafe
Joyce Chou
Rampurna Gullapalli
Patricia Frech
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38024178&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088467(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088467A publication Critical patent/ECSP088467A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una formulación farmacéutica, la cual comprende: un compuesto de la Fórmula (I), un tautómero del compuesto, una sal del compuesto, una sal del tautómero, o una mezcla de los mismos, y cuando menos un ingrediente seleccionado a partir del grupo que consiste en: (i) celulosa; (ii) dióxido de silicio; (iii) estearato de magnesio; y (iv) un ingrediente seleccionado a partir de crospovidona, almidón, o lactosa.
EC2008008467A 2005-11-29 2008-05-23 Formulaciones de quinolinonas ECSP088467A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74057705P 2005-11-29 2005-11-29
US74131705P 2005-12-01 2005-12-01

Publications (1)

Publication Number Publication Date
ECSP088467A true ECSP088467A (es) 2008-06-30

Family

ID=38024178

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008467A ECSP088467A (es) 2005-11-29 2008-05-23 Formulaciones de quinolinonas

Country Status (23)

Country Link
US (2) US20080293738A1 (es)
EP (2) EP1957074B1 (es)
JP (1) JP2009517481A (es)
KR (1) KR20080074143A (es)
CN (1) CN102670530A (es)
AR (1) AR062545A1 (es)
AU (1) AU2006320591B2 (es)
BR (1) BRPI0619370A2 (es)
CA (1) CA2627544C (es)
CL (1) CL2010000387A1 (es)
EC (1) ECSP088467A (es)
ES (1) ES2467162T3 (es)
IL (1) IL190865A0 (es)
MA (1) MA29969B1 (es)
MY (1) MY148529A (es)
NO (1) NO20082938L (es)
NZ (1) NZ567550A (es)
PE (1) PE20070760A1 (es)
PL (1) PL1957074T3 (es)
PT (1) PT1957074E (es)
RU (1) RU2433826C2 (es)
TW (1) TW200730176A (es)
WO (1) WO2007064719A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091628A1 (es) * 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
CN102137858B (zh) 2008-05-23 2014-07-23 潘米拉制药有限责任公司 5-脂氧合酶-活化蛋白抑制剂
MX2010014566A (es) * 2008-07-03 2011-02-15 Novartis Ag Proceso de granulacion de fundido.
UY33472A (es) * 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
KR20140117457A (ko) 2012-01-31 2014-10-07 노파르티스 아게 Rtk 억제제와 항에스트로겐의 조합물 및 암의 치료를 위한 그의 용도
RU2015104537A (ru) 2012-07-11 2016-08-27 Новартис Аг Способы лечения стромальных опухолей желудочно-кишечного тракта
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
BR112021009578A2 (pt) * 2018-12-06 2021-08-17 Glaxosmithkline Intellectual Property Development Limited formulação farmacêutica

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663606A (en) * 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
US4119105A (en) 1977-01-31 1978-10-10 Olin Corporation Air flow limiting filter
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JP3161780B2 (ja) 1991-09-30 2001-04-25 東レ・ダウコーニング・シリコーン株式会社 α，ω−ジヒドロキシフルオロアルキルメチルポリシロキサンの製造方法
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6010711A (en) * 1996-01-26 2000-01-04 University Of Rochester Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors
JP2000506880A (ja) 1996-03-15 2000-06-06 ゼネカ・リミテッド シンノリン誘導体及びその使用
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
WO1997048694A1 (en) 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Compounds and methods for providing pharmacologically active preparations and uses thereof
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
EP1086705A4 (en) 1998-05-20 2002-02-06 Kyowa Hakko Kogyo Kk INHIBITORS OF THE ACTIVITY OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR
US6138605A (en) 1998-08-05 2000-10-31 Seascape Systems Limited Access and evacuation apparatus with articulated arm
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US7045133B2 (en) 2000-01-18 2006-05-16 Ludwig Institute For Cancer Research VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
CN1307303C (zh) 2000-01-19 2007-03-28 帕卡什·S·吉尔 针对反义vegf寡核苷酸的方法和组合物
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
RU2274442C2 (ru) * 2000-03-07 2006-04-20 Раш-Презбитериан-Ст. Лук'С Медикал Сентер Композиции и способы улавливания и инактивации патогенных микроорганизмов и сперматозоидов
JP4341949B2 (ja) 2000-09-01 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アザ複素環式誘導体およびその治療的使用
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
JP4361727B2 (ja) 2000-09-11 2009-11-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド チロシンキナーゼインヒビターとしてのキノリノン誘導体
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
CA2501932C (en) 2002-11-13 2014-03-11 Chiron Corporation Use of benzimidazole quinolinones for treating cancer
TWI347940B (en) 2003-11-07 2011-09-01 Novartis Ag Methods for synthesizing quinolinone compounds
WO2005082340A2 (en) * 2004-02-20 2005-09-09 Chiron Corporation Modulation of inflammatory and metastatic processes
US20060261307A1 (en) * 2005-05-18 2006-11-23 Black D J Water Activated Organic Scavenger
EP2270000B1 (en) * 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts

Also Published As

Publication number Publication date
CA2627544A1 (en) 2007-06-07
TW200730176A (en) 2007-08-16
IL190865A0 (en) 2008-11-03
CN102670530A (zh) 2012-09-19
RU2433826C2 (ru) 2011-11-20
BRPI0619370A2 (pt) 2011-09-27
AU2006320591B2 (en) 2010-06-03
MY148529A (en) 2013-04-30
CA2627544C (en) 2015-07-07
WO2007064719A2 (en) 2007-06-07
PT1957074E (pt) 2014-06-25
US20080293738A1 (en) 2008-11-27
NO20082938L (no) 2008-06-30
KR20080074143A (ko) 2008-08-12
PE20070760A1 (es) 2007-10-04
US20120276200A1 (en) 2012-11-01
CL2010000387A1 (es) 2010-08-06
EP1957074A2 (en) 2008-08-20
EP2772257A1 (en) 2014-09-03
RU2008126384A (ru) 2010-01-10
JP2009517481A (ja) 2009-04-30
NZ567550A (en) 2011-08-26
AR062545A1 (es) 2008-11-19
PL1957074T3 (pl) 2014-08-29
AU2006320591A1 (en) 2007-06-07
ES2467162T3 (es) 2014-06-12
WO2007064719A3 (en) 2007-08-16
MA29969B1 (fr) 2008-11-03
EP1957074B1 (en) 2014-03-19

Similar Documents

Publication Publication Date Title
WO2007087548A3 (en) Chemical compounds
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
CO6150138A2 (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
NO20090295L (no) Substituerte heteroarylderivater
CR7928A (es) Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension
NO2012017I1 (no) Benzimidazolderivat, fremgangsmåte for fremstilling derav, medikament inneholdende denne forbindelsen samt anvendelse av forbindelsen.
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
MA30781B1 (fr) Inhibiteur de kinase
WO2006138660A3 (en) Sphingosine kinase inhibitors
AR058780A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
ES2571779T3 (es) Inhibidores de cinasa a base de nicotinamida
UY30460A1 (es) Compuestos terapéuticos
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
NO20082938L (no) Formuleringer av quinolinoner
CL2009000906A1 (es) Compuestos derivados de 4-imidazolil y 4-triazolil de 2-(6-(4-cicloalquilpiperazin-1-il)pirimidin-4-il)-1h-pirazol-3(2h)ona inhibidores de hif-prolil-4-hidroxilasas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de enfermedades cardiovasculares, renales y hematologicas.
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
WO2007002313A3 (en) Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
EA200701462A1 (ru) Распадающаяся при пероральном приёме композиция оланзапина или донепезила
EP2168964A4 (en) COUPLED AZAINDOL INDOL DERIVATIVES, MANUFACTURING METHOD AND APPLICATIONS THEREOF
DK1678162T3 (da) P-glycoprotein-inhibitor, fremgangsmåde til fremstilling heraf og farmaceutisk sammensætning omfattende denne
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
EA201101119A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента